公开(公告)号：US09404083B2

公开(公告)日：2016-08-02

申请号：US14129143

申请日：2012-06-20

申请人： Yoshikazu Yonemitsu ,  Yui Harada ,  Satoru Saito ,  Yuichiro Yazaki ,  Masato Okamoto ,  Takefumi Ishidao

发明人： Yoshikazu Yonemitsu ,  Yui Harada ,  Satoru Saito ,  Yuichiro Yazaki ,  Masato Okamoto ,  Takefumi Ishidao

IPC分类号： A61K35/28 ,  A61K38/00 ,  C12N5/0783 ,  A61K35/17

CPC分类号： C12N5/0646 ,  A61K35/17 ,  C12N2501/2302

摘要： A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy.A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.

摘要翻译： 需要一种可以在体外扩增NK细胞并为过继性免疫治疗准备最佳数量的NK细胞的技术。 提供了扩增NK细胞的方法，其包括以下步骤：制备由NK细胞组成的细胞群，从由NK细胞组成的细胞群中除去T细胞，并且在除去T细胞后，将剩余细胞培养 补充有2500至2831IU / mL的IL-2的培养基。 用于扩增本发明的NK细胞的方法可以包括从细胞群中除去造血祖细胞的步骤。 本发明提供了一种用于过继免疫治疗的药物组合物，其包含通过本发明的放大方法制备的NK细胞。

公开(公告)号：US07705196B2

公开(公告)日：2010-04-27

申请号：US10594695

申请日：2005-03-30

申请人： Tetsu Akiyama ,  Takefumi Ishidao ,  Tomoiki Aiba

发明人： Tetsu Akiyama ,  Takefumi Ishidao ,  Tomoiki Aiba

IPC分类号： G01N33/00 ,  C12Q1/00

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2267/0393 ,  G01N33/574 ,  G01N33/57484

摘要： Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg; an agent for inhibiting tumor formation or an agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP; a method of enhancing the expression and/or function of sFRP, comprising enhancing the expression and/or function of Dlg; a method of inhibiting tumor formation or a method of preventing and/or treating a tumor disease, comprising using the aforementioned enhancing agent or the aforementioned enhancing method; a non-human mammal that is deficient in one or both of Dlg alleles; a cell originating in the mammal; a method of identifying a compound, comprising using the mammal or the cell; and a method of examining a tumor tissue or a tumor cell, comprising measuring the expression and/or function of Dlg.

摘要翻译： 在Dlg基因敲除小鼠中发现了sFRP1基因和sFRP2基因的肿瘤形成和降低的转录，从而提供了以下功能：用于增强sFRP的表达和/或功能的试剂，其含有具有 增强Dlg的表达和/或功能; 用于抑制肿瘤形成的药剂或用于预防和/或治疗肿瘤疾病的药剂，其含有增强sFRP的表达和/或功能的药剂; 增强sFRP的表达和/或功能的方法，包括增强Dlg的表达和/或功能; 包括使用上述增强剂或上述增强方法的抑制肿瘤形成的方法或预防和/或治疗肿瘤疾病的方法; 缺乏一种或两种Dlg等位基因的非人哺乳动物; 起源于哺乳动物的细胞; 鉴定化合物的方法，包括使用哺乳动物或细胞; 以及检查肿瘤组织或肿瘤细胞的方法，包括测量Dlg的表达和/或功能。

公开(公告)号：US20140120072A1

公开(公告)日：2014-05-01

申请号：US14129143

申请日：2012-06-20

申请人： Yoshikazu Yonemitsu ,  Yui Harada ,  Satoru Saito ,  Yuichiro Yazaki ,  Masato Okamoto ,  Takefumi Ishidao

发明人： Yoshikazu Yonemitsu ,  Yui Harada ,  Satoru Saito ,  Yuichiro Yazaki ,  Masato Okamoto ,  Takefumi Ishidao

IPC分类号： C12N5/0783 ,  A61K35/14

CPC分类号： C12N5/0646 ,  A61K35/17 ,  C12N2501/2302

摘要： A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy.A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.

摘要翻译： 需要一种可以在体外扩增NK细胞并为过继性免疫治疗准备最佳数量的NK细胞的技术。 提供了扩增NK细胞的方法，其包括以下步骤：制备由NK细胞组成的细胞群，从由NK细胞组成的细胞群中除去T细胞，并且在除去T细胞后，将剩余细胞培养 补充有2500至2831IU / mL的IL-2的培养基。 用于扩增本发明的NK细胞的方法可以包括从细胞群中除去造血祖细胞的步骤。 本发明提供了一种用于过继免疫治疗的药物组合物，其包含通过本发明的放大方法制备的NK细胞。

公开(公告)号：US20080227695A1

公开(公告)日：2008-09-18

申请号：US10594695

申请日：2005-03-30

申请人： Tetsu Akiyama ,  Takefumi Ishidao ,  Tomoiki Aiba

发明人： Tetsu Akiyama ,  Takefumi Ishidao ,  Tomoiki Aiba

IPC分类号： A61K38/00 ,  C12N15/00 ,  C07H21/00 ,  A01K67/027 ,  C12N5/06 ,  A61P43/00 ,  C12Q1/02 ,  A61K31/70 ,  C07K14/00

CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2267/0393 ,  G01N33/574 ,  G01N33/57484

摘要： Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of enhancing the expression and/or function of Dlg; an agent for inhibiting tumor formation or an agent for preventing and/or treating a tumor disease, containing the agent for enhancing the expression and/or function of sFRP; a method of enhancing the expression and/or function of sFRP, comprising enhancing the expression and/or function of Dlg; a method of inhibiting tumor formation or a method of preventing and/or treating a tumor disease, comprising using the aforementioned enhancing agent or the aforementioned enhancing method; a non-human mammal that is deficient in one or both of Dlg alleles; a cell originating in the mammal; a method of identifying a compound, comprising using the mammal or the cell; and a method of examining a tumor tissue or a tumor cell, comprising measuring the expression and/or function of Dlg.

摘要翻译： 在Dlg基因敲除小鼠中发现了sFRP1基因和sFRP2基因的肿瘤形成和降低的转录，从而提供了以下功能：用于增强sFRP的表达和/或功能的试剂，其含有具有 增强Dlg的表达和/或功能; 用于抑制肿瘤形成的药剂或用于预防和/或治疗肿瘤疾病的药剂，其含有增强sFRP的表达和/或功能的药剂; 增强sFRP的表达和/或功能的方法，包括增强Dlg的表达和/或功能; 包括使用上述增强剂或上述增强方法的抑制肿瘤形成的方法或预防和/或治疗肿瘤疾病的方法; 缺乏一种或两种Dlg等位基因的非人哺乳动物; 起源于哺乳动物的细胞; 鉴定化合物的方法，包括使用哺乳动物或细胞; 以及检查肿瘤组织或肿瘤细胞的方法，包括测量Dlg的表达和/或功能。